Originally published by Paul Cannon.
The Johnson & Johnson subsidiary Janssen now claims that its troubled anti-diabetes drug can reduce the risk of end-stage kidney disease in some patients, so it will seek expanded government approval for Invokana. This latest announcement comes on the heels of a new clinical trial. Janssen claims that in the Canagliflozin and Renal Events in Diabetes […]
The post Janssen Asks FDA For Use Expansion Despite Invokana Litigation appeared first on .
Curated by Texas Bar Today. Follow us on Twitter @texasbartoday.
from Texas Bar Today http://bit.ly/2D22WGM
via Abogado Aly Website
No comments:
Post a Comment